- Aurobindo Pharma invested USD 145 million in its China facility.
- The plant commenced operations in November 2024.
- Break-even at EBITDA level is expected by Q3 FY26.
- The company also plans product filings in the US and Europe.
Aurobindo Pharma anticipates that its manufacturing facility in China will achieve break-even at the earnings before interest, taxes, depreciation, and amortization (EBITDA) level by the third quarter of fiscal year 2026 (Q3 FY26). The facility began operations in November 2024, and production is currently ramping up. Aurobindo has invested USD 145 million into this facility, which is part of its broader strategy to enhance its global manufacturing capabilities. In addition to the investments in China, Aurobindo is also focusing on its facilities in the United States. The company plans to file for product approvals in both the US and European markets, which could further expand its market presence and revenue streams. This strategic investment in manufacturing infrastructure is aimed at meeting increasing global demand for pharmaceuticals and improving supply chain resilience.
Insights
This break-even point will enhance Aurobindo’s financial stability and market competitiveness.